Mary Beth Dooley net worth and biography

Mary Dooley Biography and Net Worth

Insider of Synlogic

Mary Beth Dooley joined Synlogic in June 2018 and is responsible for leading the Company’s financial strategy, planning, corporate accounting and operations. Before joining Synlogic, Mary Beth worked at Idera Pharmaceuticals, where she served various roles of increasing responsibility within the finance and accounting organization. Prior to joining Idera, Mary Beth worked in the Health Industries Assurance Practice at PricewaterhouseCoopers, primarily serving clients in the life science sector. Prior to joining PricewaterhouseCoopers, she served as an Assistant Vice President at Boston Private Bank & Trust Company, in the Investment Management & Trust Department. Mary Beth holds a B.S in Economics from Bates College, a M.S. in Accounting and an M.B.A. from Northeastern University. She has participated in the Bike MS Cape Cod Getaway to help raise money and awareness for multiple sclerosis for over ten years.

What is Mary Beth Dooley's net worth?: The estimated net worth of Mary Beth Dooley is at least $14.02 thousand as of October 29th, 2025. Dooley owns 12,744 shares of Synlogic stock worth more than $14,018 as of October 5th. This net worth evaluation does not reflect any other investments that Dooley may own. Learn More about Mary Beth Dooley's net worth.
How do I contact Mary Beth Dooley?: The corporate mailing address for Dooley and other Synlogic executives is 2150 Woodward Street, Suite 100, Austin, Massachusetts, 78744. Synlogic can also be reached via phone at (617) 401-9975 and via email at [email protected]. Learn More on Mary Beth Dooley's contact information.
Has Mary Beth Dooley been buying or selling shares of Synlogic?: Mary Beth Dooley has not been actively trading shares of Synlogic during the past quarter. Most recently, Mary Beth Dooley sold 157 shares of the business's stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $1.81, for a transaction totalling $284.17. Following the completion of the sale, the insider now directly owns 12,744 shares of the company's stock, valued at $23,066.64. Learn More on Mary Beth Dooley's trading history.
Are insiders buying or selling shares of Synlogic?: During the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 157 shares worth more than $284.17. The most recent insider tranaction occured on October, 29th when insider Mary Beth Dooley sold 157 shares worth more than $284.17. Insiders at Synlogic own 2.6% of the company. Learn More about insider trades at Synlogic.
Information on this page was last updated on 10/29/2025.

Mary Beth Dooley Insider Trading History at Synlogic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/29/2025	Sell	157	$1.81	$284.17	12,744
2/3/2025	Sell	2,107	$1.33	$2,802.31	13,045
10/29/2024	Sell	79	$1.40	$110.60	15,152
4/2/2024	Sell	188	$1.73	$325.24	15,231

Mary Beth Dooley Buying and Selling Activity at Synlogic

Synlogic Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Today's Range

Now: $1.10

$1.08

$1.11

50 Day Range

MA: $1.16

$0.67

$1.23

2 Week Range

Now: $1.10

$0.54

$1.87

Volume

141,060 shs

Average Volume

67,230 shs

Market Capitalization

$13.47 million

P/E Ratio

N/A

Dividend Yield